Rimonabant: all 44 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Clinical and Neurobiological Effects of Cannabis Dependence in Young AdultsCompletedNCT00656487Phase 2Results posted
- The Effects of Rimonabant, on Weight and Metabolic Risk FactorsTerminatedNCT00547118Phase 2Results posted
- Effect of Rimonabant on Hand Function in Patients With Spinal Cord InjuryActive, not recruitingNCT07843108Phase 1/2
- Effects of CB1 Antagonist/Reverse Agonist Rimonabant on Walking Abilities in Incomplete Spinal Cord InjuryStatus unknownNCT05622994Phase 2
- Effects of Rimonabant on Walking Abilities in Incomplete Spinal Cord InjuryCompletedNCT05398913Phase 1/2
- Study of Rimonabant/Metformin Combinations to Investigate Diabetes (Blood Sugar) Control in Patients With Type 2 DiabetesWithdrawnNCT00754689Phase 3
- Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 DiabetesTerminatedNCT00690456Phase 3
- Long-Term Effect of 10 mg Versus 20 mg Rimonabant in Overweight or Obese PatientsTerminatedNCT00678483Phase 3
- Diagnosis and Therapy of Vulnerable Atherosclerotic PlaqueCompletedNCT00636766Not applicable
- Effect of Rimonabant on Weight Gain and Body Composition in Adults With Prader Willi SyndromeTerminatedNCT00603109Phase 3
- The Effect of Rimonabant on Energy Expenditure, Fat Metabolism and Body CompositionTerminatedNCT00584389Phase 4
- An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 DiabetesTerminatedNCT00577148Phase 3
- An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without DiabetesTerminatedNCT00576667Phase 3
- REASSURE: The Effect of Rimonabant on HbA1c in Overweight or Obese Patients With Type 2 Diabetes Not Adequately Controlled on 2 Oral Antidiabetic AgentsCompletedNCT00546325Phase 3
- Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese PatientsCompletedNCT00481975Phase 3
- Efficacy and Safety of Rimonabant With or Without Hypocaloric Diet in Obese PatientsCompletedNCT00481923Phase 3
- Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients on Diet and ExerciseTerminatedNCT00478972Phase 3
- Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic DrugTerminatedNCT00478595Phase 3
- Comparison of Efficacy and Safety of Rimonabant 20mg/Day Versus Placebo in Smoking CessationCompletedNCT00464256Phase 3
- Comparison of Efficacy and Safety of Rimonabant 5mg/Day or 20mg/Day Versus Placebo in Smoking CessationCompletedNCT00464165Phase 3
- Efficacy and Safety of Rimonabant as an Aid to Maintenance of Smoking CessationCompletedNCT00459173Phase 3
- Japanese Dose-Response Study of Rimonabant in Obese PatientsCompletedNCT00459004Phase 2
- Efficacy and Safety of Rimonabant as an Aid to Smoking Cessation With or Without Nicotine PatchCompletedNCT00458718Phase 3
- Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk FactorsTerminatedNCT00458081Phase 3
- A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 DiabetesTerminatedNCT00449605Phase 3
- Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS)TerminatedNCT00434096Phase 3
- European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemiaTerminatedNCT00412698Phase 3
- High Density Lipoprotein TurnoverTerminatedNCT00408148Phase 3
- Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood GlucoseTerminatedNCT00405808Phase 3
- Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)CompletedNCT00386061Phase 3
- Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Smoking Cessation (STRATUS US)CompletedNCT00358228Phase 3
- Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 DiabetesTerminatedNCT00325650Phase 3
- Study of Weight-Reducing Effect and Safety of Rimonabant In Obesity in ASIA (RIO-ASIA)CompletedNCT00325546Phase 3
- VIsceral Fat Reduction Assessed by CT-scan On RImonabAntCompletedNCT00299325Phase 3
- Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)CompletedNCT00288236Phase 3
- Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and OutcomesTerminatedNCT00263042Phase 3
- Study Evaluating Rimonabant Efficacy in Drug-NAive DiabEtic PatientsCompletedNCT00257257Phase 3
- An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese PatientsCompletedNCT00239967Phase 3
- Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on RimonabantTerminatedNCT00228176Phase 3
- STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)CompletedNCT00124332Phase 3
- Rimonabant to Reduce Alcohol ConsumptionCompletedNCT00075205Phase 2
- Obese Patients With or Without Comorbidities (RIO-North America)CompletedNCT00029861Phase 3
- Obese Patients With Type 2 DiabetesCompletedNCT00029848Phase 3
- Obese Patients With Untreated DyslipidemiasCompletedNCT00029835Phase 3